Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hermann Haller

Showing results (441-450 of 570) with videos related to

Pageof 57
Sort By:
Kidney International|April 24, 2021
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 29, 2009
Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 monthsAndreas Scherer, Wilfried Gwinner, Michael Mengel, et al.
Cardiovascular Research|July 28, 2020
Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interactionEva Roy-Chowdhury, Nicolas Brauns, Alexandra Helmke, et al.
Kidney International|April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentEric Rondeau, Marie Scully, Gema Ariceta, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 26, 2017
Longitudinal evaluation of perfusion changes in acute and chronic renal allograft rejection using arterial spin labeling in translational mouse modelsKatja Hueper, Martina Schmidbauer, Anja Thorenz, et al.
Journal of Chromatography. A|November 8, 2003
Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markersStefan Wittke, Danilo Fliser, Marion Haubitz, et al.
Journal of the American Society of Nephrology : JASN|August 30, 2008
Complement 5a receptor inhibition improves renal allograft survivalFaikah Gueler, Song Rong, Wilfried Gwinner, et al.
Kidney International Reports|September 11, 2018
The Circular RNA Malte Kölling, Harald Seeger, George Haddad, et al.
Plos One|September 15, 2010
Cofilin-1 inactivation leads to proteinuria--studies in zebrafish, mice and humansSharon Ashworth, Beina Teng, Jessica Kaufeld, et al.
Critical Care (London, England)|October 31, 2018
Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markersHannah Knaup, Klaus Stahl, Bernhard M W Schmidt, et al.
Pageof 57

Showing results (441-450 of 570) with videos related to

Sort By:
Pageof 57
Kidney International|April 24, 2021
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 29, 2009
Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 monthsAndreas Scherer, Wilfried Gwinner, Michael Mengel, et al.
Cardiovascular Research|July 28, 2020
Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interactionEva Roy-Chowdhury, Nicolas Brauns, Alexandra Helmke, et al.
Kidney International|April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentEric Rondeau, Marie Scully, Gema Ariceta, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 26, 2017
Longitudinal evaluation of perfusion changes in acute and chronic renal allograft rejection using arterial spin labeling in translational mouse modelsKatja Hueper, Martina Schmidbauer, Anja Thorenz, et al.
Journal of Chromatography. A|November 8, 2003
Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markersStefan Wittke, Danilo Fliser, Marion Haubitz, et al.
Journal of the American Society of Nephrology : JASN|August 30, 2008
Complement 5a receptor inhibition improves renal allograft survivalFaikah Gueler, Song Rong, Wilfried Gwinner, et al.
Kidney International Reports|September 11, 2018
The Circular RNA Malte Kölling, Harald Seeger, George Haddad, et al.
Plos One|September 15, 2010
Cofilin-1 inactivation leads to proteinuria--studies in zebrafish, mice and humansSharon Ashworth, Beina Teng, Jessica Kaufeld, et al.
Critical Care (London, England)|October 31, 2018
Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markersHannah Knaup, Klaus Stahl, Bernhard M W Schmidt, et al.
Pageof 57